Loading clinical trials...
Loading clinical trials...
Purpose: To develop a real time national clinical database to support and share best practices, 1. To generate hypotheses for future clinical research 2. To understand how AMEVIVE is used in routine clinical practice/real world setting. Each patient visit will include the following observational endpoints: 1. AMEVIVE dosing 2. Number of courses 3. Concomitant treatment 4. Response to treatment (patient and physician global assessments) 5. Status of other psoriasis-related medical conditions 6. Time to re-treatment.
Age
16 - No limit years
Sex
ALL
Healthy Volunteers
No
Calgary, Alberta, Canada
Calgary, Alberta, Canada
Edmonton, Alberta, Canada
Edmonton, Alberta, Canada
Surrey, British Columbia, Canada
Vancouver, British Columbia, Canada
Vancouver, British Columbia, Canada
Victoria, British Columbia, Canada
Victoria, British Columbia, Canada
Winnipeg, Manitoba, Canada
Start Date
June 1, 2005
Primary Completion Date
May 1, 2008
Completion Date
May 1, 2008
Last Updated
November 17, 2011
426
ACTUAL participants
Lead Sponsor
Astellas Pharma Inc
NCT07116967
NCT07250802
NCT07449702
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions